Significance of VCAM-1, AOPP, HbA1c and FBG in the Treatment of Gestational Diabetes Mellitus with Metformin

DAI Li-na

PDF(2990 KB)
Welcome to Labeled Immunoassays and Clinical Medicine website!
PDF(2990 KB)
Labeled Immunoassays and Clinical Medicine ›› 2018, Vol. 25 ›› Issue (5) : 689-691. DOI: 10.11748/bjmy.issn.1006-1703.2018.05.025

Significance of VCAM-1, AOPP, HbA1c and FBG in the Treatment of Gestational Diabetes Mellitus with Metformin

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2018, 25(5): 689-691 https://doi.org/10.11748/bjmy.issn.1006-1703.2018.05.025

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(2990 KB)

Accesses

Citation

Detail
Sections
Recommended
京ICP备18063657号-1
Copyright © Labeled Immunoassays and Clinical Medicine, All Rights Reserved.
Tel: 010-68515701,68517801　Fax: 010-68533122　E-mail: bjmy@circ.com.cn
Powered by Beijing Magtech Co., Ltd.

/

〈 〉